LT2697199T - Aril- arba heteroaril- pakeistieji benzeno junginiai - Google Patents
Aril- arba heteroaril- pakeistieji benzeno junginiaiInfo
- Publication number
- LT2697199T LT2697199T LTEP12719529.5T LT12719529T LT2697199T LT 2697199 T LT2697199 T LT 2697199T LT 12719529 T LT12719529 T LT 12719529T LT 2697199 T LT2697199 T LT 2697199T
- Authority
- LT
- Lithuania
- Prior art keywords
- heteroaryl
- aryl
- substituted benzene
- benzene compounds
- compounds
- Prior art date
Links
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161474821P | 2011-04-13 | 2011-04-13 | |
US201161499595P | 2011-06-21 | 2011-06-21 | |
PCT/US2012/033648 WO2012142504A1 (en) | 2011-04-13 | 2012-04-13 | Aryl-or heteroaryl-substituted benzene compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2697199T true LT2697199T (lt) | 2016-09-26 |
Family
ID=46045109
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP16172386.1T LT3150580T (lt) | 2011-04-13 | 2012-04-13 | Aril- arba heteroaril-pakeistieji benzeno junginiai |
LTEP21175920.4T LT3943485T (lt) | 2011-04-13 | 2012-04-13 | Arilu arba heteroarilu pakeisti benzeno junginiai |
LTEP18200713.8T LT3486234T (lt) | 2011-04-13 | 2012-04-13 | Arilu arba heteroarilu pakeisti benzeno junginiai |
LTEP12719529.5T LT2697199T (lt) | 2011-04-13 | 2012-04-13 | Aril- arba heteroaril- pakeistieji benzeno junginiai |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP16172386.1T LT3150580T (lt) | 2011-04-13 | 2012-04-13 | Aril- arba heteroaril-pakeistieji benzeno junginiai |
LTEP21175920.4T LT3943485T (lt) | 2011-04-13 | 2012-04-13 | Arilu arba heteroarilu pakeisti benzeno junginiai |
LTEP18200713.8T LT3486234T (lt) | 2011-04-13 | 2012-04-13 | Arilu arba heteroarilu pakeisti benzeno junginiai |
Country Status (36)
Country | Link |
---|---|
US (11) | US8410088B2 (lt) |
EP (5) | EP3943485B1 (lt) |
JP (6) | JP5933686B2 (lt) |
KR (7) | KR101914321B1 (lt) |
CN (2) | CN107311921B (lt) |
AR (1) | AR086008A1 (lt) |
AU (1) | AU2012242595B2 (lt) |
BR (2) | BR122020006541B1 (lt) |
CA (2) | CA3086473A1 (lt) |
CL (1) | CL2013002898A1 (lt) |
CY (3) | CY1117986T1 (lt) |
DK (4) | DK3150580T3 (lt) |
ES (3) | ES2706951T3 (lt) |
FI (1) | FI3943485T3 (lt) |
HK (1) | HK1193804A1 (lt) |
HR (3) | HRP20211297T8 (lt) |
HU (3) | HUE028837T2 (lt) |
IL (3) | IL228745A (lt) |
JO (2) | JO3438B1 (lt) |
LT (4) | LT3150580T (lt) |
ME (1) | ME02500B (lt) |
MX (2) | MX343685B (lt) |
MY (1) | MY166171A (lt) |
NZ (3) | NZ734744A (lt) |
PE (1) | PE20140863A1 (lt) |
PH (1) | PH12016502132A1 (lt) |
PL (3) | PL3486234T3 (lt) |
PT (4) | PT3943485T (lt) |
RS (3) | RS58226B1 (lt) |
RU (1) | RU2632193C2 (lt) |
SG (1) | SG194447A1 (lt) |
SI (3) | SI3486234T1 (lt) |
SM (1) | SMT201600308B (lt) |
TW (1) | TWI529162B (lt) |
WO (1) | WO2012142504A1 (lt) |
ZA (1) | ZA201307539B (lt) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
RU2618475C2 (ru) | 2010-09-10 | 2017-05-03 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
CA2850570A1 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CA2862289C (en) * | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
ES2718900T3 (es) * | 2012-03-12 | 2019-07-05 | Epizyme Inc | Inhibidores de EZH2 humana y métodos de uso de los mismos |
KR20230004871A (ko) * | 2012-04-13 | 2023-01-06 | 에피자임, 인코포레이티드 | 암 치료용 병용 요법 |
SG11201406468YA (en) * | 2012-04-13 | 2015-01-29 | Epizyme Inc | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
JP6254169B2 (ja) * | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
NZ706836A (en) | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
PE20150887A1 (es) * | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
EP2931707A4 (en) | 2012-12-13 | 2016-07-20 | Glaxosmithkline Llc | AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS |
EP2934531A4 (en) * | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
US20150344427A1 (en) * | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | 1,4-pyridone compounds |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
CN105102446B (zh) * | 2013-02-11 | 2018-01-23 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物及用途 |
WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
LT2970132T (lt) | 2013-03-14 | 2021-01-11 | Epizyme, Inc. | Argininmetiltransferazės inhibitoriai ir jų panaudojimas |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US20160039767A1 (en) | 2013-03-14 | 2016-02-11 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
CA2905070A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
WO2014153100A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970220A2 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
AU2014254392B2 (en) | 2013-03-15 | 2018-05-24 | Epizyme, Inc. | Substituted benzene compounds |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2991980B1 (en) | 2013-04-30 | 2019-01-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
EP3004096A1 (en) * | 2013-06-06 | 2016-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
US9556157B2 (en) | 2013-07-10 | 2017-01-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
AU2014337300B2 (en) * | 2013-10-16 | 2019-01-03 | Eisai R&D Management Co., Ltd. | Hydrochloride salt form for EZH2 inhibition |
US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
US9822103B2 (en) | 2013-11-22 | 2017-11-21 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
ES2863996T3 (es) | 2013-12-06 | 2021-10-13 | Epizyme Inc | Terapia de combinación para el tratamiento del cáncer |
CN105037360B (zh) * | 2014-04-28 | 2016-08-17 | 四川大学 | 吡啶酮衍生物及其制备方法和用途 |
CN106999498B (zh) | 2014-06-17 | 2021-06-08 | Epizyme股份有限公司 | 用于治疗淋巴瘤的ezh2抑制剂 |
CR20160574A (es) | 2014-06-17 | 2017-02-23 | Pfizer | Compuestos de dihidroisoquinolinona sustituida |
WO2015200650A1 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
MX2017004969A (es) | 2014-10-16 | 2017-07-19 | Epizyme Inc | Metodo para tratar el cancer. |
WO2016066697A1 (en) * | 2014-10-28 | 2016-05-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
WO2016073956A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
BR112017010166A2 (pt) | 2014-11-17 | 2018-02-14 | Eisai R&D Man Co Ltd | método de tratamento de um tumor sólido, método de inibição da atividade, forma de dosagem oral para o tratamento de um tumor sólido, formulação farmacêutica sólida, processo para a preparação de uma formulação farmacêutica, e, composição farmacêutica sólida |
TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ezh2抑制劑 |
EP3285773A4 (en) * | 2015-04-20 | 2019-04-10 | Epizyme, Inc. | POLY THERAPY FOR THE TREATMENT OF CANCER |
EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
US20190083504A1 (en) | 2015-10-06 | 2019-03-21 | Epizyme, Inc. | Method of treating medulloblastoma with an ezh2 inhibitor |
WO2017079757A1 (en) * | 2015-11-06 | 2017-05-11 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
LT3378859T (lt) | 2015-11-19 | 2020-01-27 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofurano darinys, jo gavimo būdas ir jo panaudojimas medicinoje |
CN105440023A (zh) * | 2015-12-10 | 2016-03-30 | 江苏理工学院 | Epz-6438的合成方法 |
TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
CA3011186A1 (en) * | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
WO2017174023A1 (zh) * | 2016-04-08 | 2017-10-12 | 南京明德新药研发股份有限公司 | 作为ezh2抑制剂的联苯化合物 |
US10633371B2 (en) * | 2016-04-22 | 2020-04-28 | Dana-Farber Cancer Institute, Inc. | EZH2 inhibitors and uses thereof |
US10987353B2 (en) | 2016-05-04 | 2021-04-27 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs |
US10604531B2 (en) | 2016-05-05 | 2020-03-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
CA3025933A1 (en) * | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
MA45406A (fr) | 2016-06-17 | 2019-04-24 | Epizyme Inc | Inhibiteurs d'ezh2 pour traiter le cancer |
EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
EP3548032A2 (en) | 2016-12-02 | 2019-10-09 | Epizyme, Inc. | Combination therapy for treating cancer |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
CN108314677B (zh) | 2017-01-17 | 2020-06-30 | 安徽中科拓苒药物科学研究有限公司 | 一种ezh2抑制剂及其用途 |
WO2018135556A1 (ja) | 2017-01-19 | 2018-07-26 | 第一三共株式会社 | Htlv-1関連脊髄症を治療することに用いるための医薬組成物 |
WO2018137639A1 (zh) | 2017-01-25 | 2018-08-02 | 恩瑞生物医药科技(上海)有限公司 | 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
CA3060416A1 (en) * | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
CA3058496A1 (en) | 2017-05-18 | 2018-11-22 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal of benzofuran derivative free base and preparation method |
US11602529B2 (en) | 2017-06-02 | 2023-03-14 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
WO2018231973A1 (en) | 2017-06-13 | 2018-12-20 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
JP7399079B2 (ja) * | 2017-09-05 | 2023-12-15 | エピザイム,インコーポレイティド | 癌を処置するための併用療法 |
US11529344B2 (en) | 2017-11-14 | 2022-12-20 | Pfizer Inc. | EZH2 inhibitor combination therapies |
DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
CN108640842B (zh) * | 2018-04-04 | 2021-06-04 | 大连九信精细化工有限公司 | 一种2-溴-5-氟硝基苯的合成方法 |
EP3802627A4 (en) | 2018-06-07 | 2022-03-09 | Merck Sharp & Dohme Corp. | METHODS OF PREPARING SUGAMMADEX |
JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのprc2サブユニットの阻害 |
CN111683936B (zh) * | 2018-07-27 | 2021-08-20 | 苏州信诺维医药科技股份有限公司 | 多取代苯环化合物、制备方法及其用途 |
KR20200101219A (ko) | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
EP3950676A4 (en) * | 2019-03-25 | 2022-08-10 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | METHOD FOR THE PREPARATION OF AMIDE COMPOUND AND ITS APPLICATION IN THE FIELD OF MEDICINE |
WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
CN115551842B (zh) * | 2020-06-08 | 2024-04-23 | 南京明德新药研发有限公司 | 联苯类化合物 |
EP4230625A1 (en) * | 2020-10-13 | 2023-08-23 | Evopoint Biosciences Co., Ltd. | Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof |
CN114907300A (zh) * | 2021-02-08 | 2022-08-16 | 上海医药工业研究院 | 他泽司他关键中间体的制备方法及其中间体 |
CN114907299A (zh) * | 2021-02-08 | 2022-08-16 | 上海医药工业研究院 | 他泽司他关键中间体的新盐型、其制备方法及其中间体 |
CN113292489B (zh) * | 2021-06-16 | 2022-08-30 | 泓博智源(开原)药业有限公司 | 二氯代二烷基烟腈的制备方法 |
CN113527275A (zh) * | 2021-07-20 | 2021-10-22 | 成都师范学院 | 一种sklb1039化合物及其制备方法和应用 |
CN113582863B (zh) * | 2021-08-19 | 2023-05-26 | 沈阳农业大学 | 一种氨乙基联苯类化合物及其制备方法和用途 |
KR20230081459A (ko) | 2021-11-30 | 2023-06-07 | 엘젠테라퓨틱스 주식회사 | 헤테로사이클릭이 치환된 신규한 3-페닐피리딘과 4-페닐피리딘 유도체 및 이의 용도 |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
CN115197202B (zh) * | 2022-07-15 | 2024-01-26 | 四川大学 | 一种ezh2共价抑制剂及其制备方法和应用 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | N−シアノ−n′−置換−アリールカルボキシイミダミド化合物の製造法 |
AU694465B2 (en) | 1993-12-27 | 1998-07-23 | Eisai Co. Ltd. | Anthranilic acid derivative |
DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
AU6060099A (en) | 1998-09-30 | 2000-04-17 | Procter & Gamble Company, The | 2-substituted ketoamides |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
ATE438624T1 (de) | 2000-12-28 | 2009-08-15 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
EP1363702A4 (en) * | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
EP2281564A3 (en) | 2002-12-27 | 2012-09-05 | Sucampo AG | Derivatives of prostaglandins for treating abdominal discomfort |
GEP20084341B (en) * | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
ATE532781T1 (de) | 2003-06-19 | 2011-11-15 | Glaxosmithkline Llc | 5-(acylamino)indazol-derivate als kinase- inhibitoren |
UA84156C2 (ru) * | 2003-07-23 | 2008-09-25 | Байер Фармасьютикалс Корпорейшн | Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний |
ATE462426T1 (de) | 2003-08-26 | 2010-04-15 | Merck Hdac Res Llc | Verwendung von saha zur behandlung von mesotheliom |
US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
BRPI0508579A (pt) | 2004-03-11 | 2007-08-14 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
CN1286973C (zh) | 2004-04-12 | 2006-11-29 | 上海第二医科大学附属瑞金医院 | 一种组蛋白甲基转移酶及其制备方法 |
JP5160885B2 (ja) | 2004-06-01 | 2013-03-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法 |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
EP1891434B1 (en) | 2005-06-02 | 2011-01-05 | The University of North Carolina at Chapel Hill | Purification, characterization and reconstitution of a ubiquitin e3 ligase |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
NZ593684A (en) | 2005-10-19 | 2012-11-30 | Gruenenthal Chemie | Novel vanilloid receptor ligands and their use for producing medicaments |
WO2007050347A1 (en) | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Potassium channel inhibitors |
CA2622615A1 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
WO2007087015A1 (en) | 2006-01-20 | 2007-08-02 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
RU2008149246A (ru) | 2006-05-15 | 2010-06-20 | Айрм Ллк (Bm) | Соединение на основе терефталата, композиции и их применение в качестве ингибиторов интегразы вич |
US20070287706A1 (en) | 2006-05-18 | 2007-12-13 | Dickson John K Jr | Certain substituted quinolones, compositions, and uses thereof |
EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | NEUROPROTEKTIVE COMPOSITIONS AND METHOD |
WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
WO2008109534A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof |
WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
JP5364875B2 (ja) | 2007-07-16 | 2013-12-11 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬としてのインダゾール類、ベンゾイソオキサゾール類およびベンゾイソチアゾール類 |
AU2008319308B2 (en) * | 2007-10-31 | 2013-01-31 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
JP5511680B2 (ja) | 2007-12-19 | 2014-06-04 | キャンサー・リサーチ・テクノロジー・リミテッド | ピリド[2,3−b]ピラジン−8−置換化合物及びその使用 |
CN101977905B (zh) * | 2008-01-23 | 2014-07-02 | 百时美施贵宝公司 | 4-吡啶酮化合物及其对于癌症的用途 |
WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
UY31982A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
EP2323660A2 (en) | 2008-08-08 | 2011-05-25 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
MX2011010062A (es) * | 2009-03-24 | 2011-11-18 | Sanofi Sa | Derivados de azacarbolinas 9h-pirrolo [2,3-b:5,4-c´] dipiridina, su preparacion y su uso en terapeutica. |
WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
WO2011082044A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
BR112012028556A2 (pt) * | 2010-05-07 | 2014-04-01 | Glaxosmithkline Llc | Indóis |
US8846935B2 (en) * | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
WO2012005805A1 (en) * | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
RU2618475C2 (ru) | 2010-09-10 | 2017-05-03 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
JP5908493B2 (ja) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | インドール |
RU2013130253A (ru) | 2010-12-03 | 2015-01-10 | Эпизайм, Инк. | 7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
CA2850570A1 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
ES2718900T3 (es) | 2012-03-12 | 2019-07-05 | Epizyme Inc | Inhibidores de EZH2 humana y métodos de uso de los mismos |
SG11201406468YA (en) | 2012-04-13 | 2015-01-29 | Epizyme Inc | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
KR20230004871A (ko) | 2012-04-13 | 2023-01-06 | 에피자임, 인코포레이티드 | 암 치료용 병용 요법 |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
NZ706836A (en) | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
PE20150887A1 (es) | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
-
2011
- 2011-04-13 JO JOP/2018/0104A patent/JO3438B1/ar active
-
2012
- 2012-04-10 JO JOP/2012/0087A patent/JO3363B1/ar active
- 2012-04-12 TW TW101112994A patent/TWI529162B/zh active
- 2012-04-13 PL PL18200713T patent/PL3486234T3/pl unknown
- 2012-04-13 EP EP21175920.4A patent/EP3943485B1/en active Active
- 2012-04-13 MX MX2013011921A patent/MX343685B/es active IP Right Grant
- 2012-04-13 HU HUE12719529A patent/HUE028837T2/en unknown
- 2012-04-13 DK DK16172386.1T patent/DK3150580T3/en active
- 2012-04-13 EP EP18200713.8A patent/EP3486234B1/en active Active
- 2012-04-13 PT PT211759204T patent/PT3943485T/pt unknown
- 2012-04-13 SI SI201231941T patent/SI3486234T1/sl unknown
- 2012-04-13 KR KR1020137029930A patent/KR101914321B1/ko active Application Filing
- 2012-04-13 AR ARP120101288A patent/AR086008A1/es active IP Right Grant
- 2012-04-13 ES ES16172386T patent/ES2706951T3/es active Active
- 2012-04-13 PE PE2013002280A patent/PE20140863A1/es active IP Right Grant
- 2012-04-13 NZ NZ734744A patent/NZ734744A/en unknown
- 2012-04-13 HR HRP20211297TT patent/HRP20211297T8/hr unknown
- 2012-04-13 PT PT127195295T patent/PT2697199T/pt unknown
- 2012-04-13 KR KR1020197005890A patent/KR102032303B1/ko active IP Right Grant
- 2012-04-13 KR KR1020207024969A patent/KR102308488B1/ko active IP Right Grant
- 2012-04-13 RS RS20190065A patent/RS58226B1/sr unknown
- 2012-04-13 EP EP16172386.1A patent/EP3150580B1/en active Active
- 2012-04-13 AU AU2012242595A patent/AU2012242595B2/en active Active
- 2012-04-13 PL PL16172386T patent/PL3150580T3/pl unknown
- 2012-04-13 PT PT182007138T patent/PT3486234T/pt unknown
- 2012-04-13 HU HUE18200713A patent/HUE056552T2/hu unknown
- 2012-04-13 KR KR1020187030566A patent/KR101955871B1/ko active IP Right Grant
- 2012-04-13 BR BR122020006541-9A patent/BR122020006541B1/pt active IP Right Grant
- 2012-04-13 EP EP12719529.5A patent/EP2697199B1/en active Active
- 2012-04-13 ME MEP-2016-175A patent/ME02500B/me unknown
- 2012-04-13 LT LTEP16172386.1T patent/LT3150580T/lt unknown
- 2012-04-13 PT PT16172386T patent/PT3150580T/pt unknown
- 2012-04-13 CA CA3086473A patent/CA3086473A1/en active Pending
- 2012-04-13 MY MYPI2013003694A patent/MY166171A/en unknown
- 2012-04-13 KR KR1020217030083A patent/KR102566864B1/ko active IP Right Grant
- 2012-04-13 RS RS20160706A patent/RS55113B1/sr unknown
- 2012-04-13 US US13/447,007 patent/US8410088B2/en active Active
- 2012-04-13 DK DK12719529.5T patent/DK2697199T3/en active
- 2012-04-13 ES ES18200713T patent/ES2886099T3/es active Active
- 2012-04-13 EP EP23217912.7A patent/EP4360712A2/en active Pending
- 2012-04-13 JP JP2014505372A patent/JP5933686B2/ja active Active
- 2012-04-13 FI FIEP21175920.4T patent/FI3943485T3/fi active
- 2012-04-13 NZ NZ717119A patent/NZ717119A/en unknown
- 2012-04-13 CN CN201710425075.8A patent/CN107311921B/zh active Active
- 2012-04-13 SI SI201231505T patent/SI3150580T1/sl unknown
- 2012-04-13 NZ NZ616298A patent/NZ616298A/en unknown
- 2012-04-13 WO PCT/US2012/033648 patent/WO2012142504A1/en active Application Filing
- 2012-04-13 LT LTEP21175920.4T patent/LT3943485T/lt unknown
- 2012-04-13 PL PL12719529.5T patent/PL2697199T3/pl unknown
- 2012-04-13 LT LTEP18200713.8T patent/LT3486234T/lt unknown
- 2012-04-13 CA CA2832843A patent/CA2832843C/en active Active
- 2012-04-13 SG SG2013075478A patent/SG194447A1/en unknown
- 2012-04-13 LT LTEP12719529.5T patent/LT2697199T/lt unknown
- 2012-04-13 KR KR1020237027131A patent/KR20230134128A/ko active Search and Examination
- 2012-04-13 CN CN201280029207.0A patent/CN104080769B/zh active Active
- 2012-04-13 BR BR112013026324-5A patent/BR112013026324B1/pt active IP Right Grant
- 2012-04-13 ES ES12719529.5T patent/ES2589555T3/es active Active
- 2012-04-13 DK DK18200713.8T patent/DK3486234T3/da active
- 2012-04-13 RS RS20211082A patent/RS62279B1/sr unknown
- 2012-04-13 HU HUE16172386A patent/HUE042788T2/hu unknown
- 2012-04-13 DK DK21175920.4T patent/DK3943485T3/da active
- 2012-04-13 KR KR1020197029487A patent/KR102154946B1/ko active IP Right Grant
- 2012-04-13 RU RU2013150345A patent/RU2632193C2/ru active
- 2012-04-13 SI SI201230695A patent/SI2697199T1/sl unknown
- 2012-12-20 US US13/722,807 patent/US8765732B2/en active Active
-
2013
- 2013-10-06 IL IL228745A patent/IL228745A/en active IP Right Grant
- 2013-10-09 ZA ZA2013/07539A patent/ZA201307539B/en unknown
- 2013-10-10 CL CL2013002898A patent/CL2013002898A1/es unknown
- 2013-10-11 MX MX2020012695A patent/MX2020012695A/es unknown
-
2014
- 2014-05-12 US US14/275,667 patent/US9090562B2/en active Active
- 2014-07-11 HK HK14107089.1A patent/HK1193804A1/zh unknown
-
2015
- 2015-06-17 US US14/742,481 patent/US9549931B2/en active Active
- 2015-10-06 US US14/876,658 patent/US9522152B2/en active Active
-
2016
- 2016-03-14 JP JP2016050059A patent/JP2016147886A/ja not_active Withdrawn
- 2016-09-01 HR HRP20161115TT patent/HRP20161115T1/hr unknown
- 2016-09-07 CY CY20161100879T patent/CY1117986T1/el unknown
- 2016-09-08 SM SM201600308T patent/SMT201600308B/it unknown
- 2016-10-25 PH PH12016502132A patent/PH12016502132A1/en unknown
- 2016-11-08 US US15/346,677 patent/US10155002B2/en active Active
- 2016-11-29 IL IL249273A patent/IL249273B/en active IP Right Grant
-
2017
- 2017-05-17 US US15/598,078 patent/US9855275B2/en active Active
- 2017-11-17 US US15/816,907 patent/US10420775B2/en active Active
-
2018
- 2018-02-14 JP JP2018024505A patent/JP6778226B2/ja active Active
- 2018-09-27 JP JP2018181993A patent/JP2019014732A/ja active Pending
-
2019
- 2019-01-11 HR HRP20190074TT patent/HRP20190074T1/hr unknown
- 2019-01-14 CY CY191100038T patent/CY1121120T1/el unknown
- 2019-03-04 US US16/291,800 patent/US20190192526A1/en not_active Abandoned
- 2019-05-02 IL IL266418A patent/IL266418A/en active IP Right Grant
- 2019-10-22 US US16/660,339 patent/US11052093B2/en active Active
-
2020
- 2020-11-27 JP JP2020197115A patent/JP2021042243A/ja not_active Withdrawn
-
2021
- 2021-05-05 US US17/308,610 patent/US20210379076A1/en active Pending
- 2021-08-31 CY CY20211100771T patent/CY1124617T1/el unknown
-
2022
- 2022-11-11 JP JP2022181039A patent/JP2023011933A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL266418A (en) | Aryl or heteroaryl substituted benzene compounds | |
IL265437A (en) | Converted gasoline compounds | |
HK1202534A1 (en) | Substituted benzene compounds | |
HK1192246A1 (en) | Substituted phenyl compounds | |
GB201119591D0 (en) | New compounds II | |
GB201113971D0 (en) | New compounds ii |